AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines
31 Luglio 2024 - 3:00PM
Business Wire
AbCellera (Nasdaq: ABCL) announced today that it has expanded
its existing collaboration with Eli Lilly and Company (Lilly) to
discover therapeutic antibodies for programs in immunology,
cardiovascular disease, and neuroscience. The expansion builds upon
the successful research collaboration established in March 2020,
which included eight de novo programs for targets selected by Lilly
and an exclusive license to AbCellera’s COVID-19 antibody
program.
AbCellera has advanced all eight programs under the original
agreement, and the licensed program resulted in emergency use
authorization by the U.S. Food and Drug Administration for two
COVID-19 antibody therapies co-developed by the companies.
“Lilly has been a terrific partner and is one of the most
admired and innovative pharmaceutical companies in the world," said
Carl Hansen, Ph.D., founder and CEO of AbCellera. “We are excited
to deepen our partnership and potentially increase our impact on
patients across multiple therapeutic areas.”
Under the expanded agreement, Lilly has the right to develop and
commercialize therapeutic antibodies resulting from the
collaboration. AbCellera has received an upfront payment, will
receive research payments, and is eligible to receive downstream
milestone payments and royalties on net product sales.
About AbCellera Biologics Inc.
AbCellera (Nasdaq: ABCL) discovers and develops antibody
medicines for indications across therapeutic areas, including
cancer, metabolic and endocrine conditions, and autoimmune
disorders. AbCellera’s engine integrates technology, data science,
infrastructure, and interdisciplinary teams to solve the most
challenging antibody discovery problems. AbCellera is focused on
advancing an internal pipeline of first-in-class and best-in-class
programs and collaborating on innovative drug development programs
with partners. For more information, please visit
www.abcellera.com.
AbCellera Forward-Looking Statements
This press release contains forward-looking statements,
including statements made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. The
forward-looking statements are based on management’s current
beliefs and assumptions and on information currently available to
management. All statements contained in this release other than
statements of historical fact are forward-looking statements,
including statements regarding our ability to develop,
commercialize, and achieve market acceptance of our current and
planned products and services, our research and development
efforts, and other matters regarding our business strategies, use
of capital, results of operations and financial position, and plans
and objectives for future operations.
In some cases, you can identify forward-looking statements by
the words “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties, and other factors that may cause
actual results, levels of activity, performance, or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. These risks, uncertainties,
and other factors are described under “Risk Factors,” “Management's
Discussion and Analysis of Financial Condition and Results of
Operations,” and elsewhere in the documents we file with the
Securities and Exchange Commission from time to time. We caution
you that forward-looking statements are based on a combination of
facts and factors currently known by us and our projections of the
future, about which we cannot be certain. As a result, the
forward-looking statements may not prove to be accurate. The
forward-looking statements in this press release represent our
views as of the date hereof. We undertake no obligation to update
any forward-looking statements for any reason, except as required
by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240731236547/en/
Inquiries Media: Kathleen Reid; media@abcellera.com,
+1(236)521-6774 Business Development: Murray McCutcheon, Ph.D.;
bd@abcellera.com, +1(604)559-9005 Investor Relations: Melanie
Solomon; ir@abcellera.com, +1(778)729-9116
Grafico Azioni AbCellera Biologics (NASDAQ:ABCL)
Storico
Da Lug 2024 a Ago 2024
Grafico Azioni AbCellera Biologics (NASDAQ:ABCL)
Storico
Da Ago 2023 a Ago 2024